Companies
Shilpa Medicare
Shilpa Medicare's wholly-owned subsidiary Shilpa Biocare Private Limited signed an exclusive European commercialization agreement with Finland-based Orion Corporation for Shilpa's recombinant human albumin (announced Q1 FY26 / late June 2026 disclosure) — Orion gains exclusive distribution,…
- Country
- India
- Ticker
- BSE:530549
First Indian rHA Phase 1 completion Aug 2024; Orion Corporation Europe commercialization via Shilpa Biocare (Q1 FY26)
in
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | The company receives development and regulatory milestone payments from Orion Corporation under their partnership agreements. | pharmafile.com · vbshilpa.com · businesswire.com · orionpharma.com |
| Capacity | 200KL+ fermentation capacity, with capacities ranging from 5 KL to 50 KL for product vessels and 5 KL to 15 KL for buffer vessels. | vbshilpa.com · bseindia.com |
| Certification | Manufacturing facilities hold various certifications including US FDA, EU GMP, WHO-GMP, TGA, PMDA, KFDA, ANVISA, COFEPRIS, and Health Canada. | vbshilpa.com · bseindia.com |
| Regulatory approval | The company maintains regulatory approvals from bodies including US FDA, EU GMP, PMDA, KFDA, and TGA. | vbshilpa.com · bseindia.com |
| Production site | Facilities include API Units 1 and 2 in Raichur, Formulations units in Jadcherla and Bangalore, and a Biologics site in Dharwad. | vbshilpa.com · bseindia.com |
| Headcount | 1,059 total employees worldwide as of March 2026. | finance.yahoo.com |
| Revenue | INR 1,549 crores for the full year ended 31 March 2026. | bseindia.com · vbshilpa.com |
Independent sources: bseindia.com · businesswire.com · finance.yahoo.com · orionpharma.com · pharmafile.com · vbshilpa.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant human serum albumin (rHSA) | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.